Nana Petroula, Kouvelos George, Behrendt Christian-Alexander, Giannoukas Athanasios, Kölbel Tilo, Spanos Konstantinos
Vascular Surgery Department, Larissa University Hospital, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece.
German Aortic Center, Department of Vascular Medicine, University Heart and Vascular Center UKE Hamburg, 20251 Hamburg, Germany.
Rev Cardiovasc Med. 2023 Jan 31;24(2):34. doi: 10.31083/j.rcm2402034. eCollection 2023 Feb.
Extended downstream endovascular management has been applied in acute complicated type B aortic dissection (acTBAD), distally to standard thoracic endovascular aortic repair (TEVAR), using bare metal stents, with or without lamina disruption, using balloon inflation. The aim of this systematic review was to assess technical success, 30-day mortality, and mortality during follow-up in patients with acTBAD managed with the Provisional Extension To Induce Complete Attachment (PETTICOAT) or stent-assisted balloon-induced intimal disruption and relamination (STABILISE) technique.
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 statement was followed. A search of the English literature, via Ovid, using MEDLINE, EMBASE, and CENTRAL databases, until 30th August 2022, was executed. Randomized controlled trials and observational studies (published between 2000-2022), with 5 patients, reporting on technical success, 30-day mortality and mortality during the available follow-up among patients that underwent PETTICOAT or STABILISE technique for acTBAD were eligible. The Newcastle-Ottawa Scale was applied to assess the risk of bias. Primary outcomes were technical success and 30-day mortality, and secondary outcome was mortality during the available follow-up.
Thirteen studies were considered eligible, twelve in the quantitative analysis. In total, 418 patients with acTBAD managed with the PETTICOAT (83%) or STABILISE (17%) technique were included. Technical success ranged between 97-100%, 99% for the PETTICOAT and 100% for the STABILISE sub-cohort. Thirty-day mortality was estimated at 3.7% (12/321), 1.4% for the STABILISE and 4.4% for the PETTICOAT technique. All studies reported the mean available follow-up which was estimated at 20 months (range 3-168 months), 22 months (mean value) for the PETTICOAT and 17 months (mean value) for the STABILISE technique. Twenty-three patients died during follow-up, with an estimated mortality rate at 5.7% for the total cohort. The mortality during follow-up was 0% for the STABILISE and 7.0% for the PETTICOAT approach.
Both, the PETTICOAT and STABILISE techniques presented less than 4% perioperative mortality in patients with acTBAD with high technical success rate. The mid-term mortality rate was at 6%. However, the heterogeneity in the available studies' highlights the need for further prospective studies, including larger volume and longer follow-up.
在急性复杂性B型主动脉夹层(acTBAD)中,已将标准胸段血管腔内主动脉修复术(TEVAR)远端的下游血管腔内管理应用于裸金属支架,无论有无内膜破裂,均采用球囊扩张。本系统评价的目的是评估采用临时延伸以诱导完全附着(PETTICOAT)或支架辅助球囊诱导内膜破裂和重新内膜化(STABILISE)技术治疗的acTBAD患者的技术成功率、30天死亡率和随访期间的死亡率。
遵循系统评价和Meta分析的首选报告项目(PRISMA)2020声明。通过Ovid对英文文献进行检索,使用MEDLINE、EMBASE和CENTRAL数据库,直至2022年8月30日。纳入2000 - 2022年间发表的、涉及5例患者的随机对照试验和观察性研究,这些研究报告了接受PETTICOAT或STABILISE技术治疗acTBAD患者的技术成功率、30天死亡率和可用随访期间的死亡率。应用纽卡斯尔 - 渥太华量表评估偏倚风险。主要结局为技术成功率和30天死亡率,次要结局为可用随访期间的死亡率。
13项研究被认为符合纳入标准,12项纳入定量分析。总共纳入了418例接受PETTICOAT(83%)或STABILISE(17%)技术治疗的acTBAD患者。技术成功率在97% - 100%之间,PETTICOAT亚组为99%,STABILISE亚组为100%。30天死亡率估计为3.7%(12/321),STABILISE技术为1.4%,PETTICOAT技术为4.4%。所有研究均报告了平均可用随访时间,估计为20个月(范围3 - 168个月),PETTICOAT技术为22个月(平均值),STABILISE技术为17个月(平均值)。23例患者在随访期间死亡,整个队列的估计死亡率为5.7%。STABILISE技术随访期间死亡率为0%,PETTICOAT技术为7.0%。
PETTICOAT和STABILISE技术在acTBAD患者中的围手术期死亡率均低于4%,技术成功率高。中期死亡率为6%。然而,现有研究的异质性凸显了进一步开展前瞻性研究的必要性,包括更大样本量和更长随访时间。